BIOFRONTERA AG/ADR (NASDAQ:BFRA) had its price objective upped by Lake Street Capital from $19.00 to $24.00 in a research note released on Tuesday, April 30th, The Fly reports. The firm currently has a buy rating on the stock.
Separately, Benchmark restated a buy rating on shares of BIOFRONTERA AG/ADR in a research note on Tuesday, March 26th.
NASDAQ:BFRA remained flat at $$14.72 during midday trading on Tuesday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 3.14 and a current ratio of 3.55. BIOFRONTERA AG/ADR has a fifty-two week low of $11.04 and a fifty-two week high of $16.06. The company has a market cap of $328.48 million, a P/E ratio of -31.31 and a beta of 1.10.
BIOFRONTERA AG/ADR (NASDAQ:BFRA) last released its earnings results on Monday, April 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). The business had revenue of $7.48 million during the quarter. BIOFRONTERA AG/ADR had a negative return on equity of 86.27% and a negative net margin of 71.00%.
BIOFRONTERA AG/ADR Company Profile
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.
Recommended Story: What is a conference call?
Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.